Georgios Stamatakos
In silico medicine, an emergent scientific and technological discipline based on clinically driven and oriented multiscale biomodeling, appears to be one of the latest trends regarding the translation of mathematical and computational biological science to clinical practice through massive exploitation of information technology. In silico (i.e. on the computer) experimentation for each individual patient using their own multiscale biomedical data (molecular, histological, imaging etc.) is expected to significantly improve the effectiveness of treatment since reliable computer predictions could suggest the optimal treatment scheme(s) and schedules(s) for each separate case. The Oncosimulator is an information technology system simulating in vivo tumor response to therapeutic modalities within the clinical trial context. The major components, the mathematical approaches and techniques and the function of the technologically Integrated Oncosimulator (IOS) and the Hypermodel based Oncosimulator (HOS) developed within then the framework of several large scale European Commission co-funded projects including ACGT, p-medicine and the EU-US project CHIC are outlined. The technology modules include inter alia multiscale data handling, image processing, execution of the code on the grid/cloud and visualization of the predictions. IOS and HOS appear to be the first worldwide efforts of their kind. In the pediatric oncology context a nephroblastoma, a glioblastoma and an acute lymphocyte leukemia oncosimulators are currently undergoing clinical validation within the framework of real clinical trials. Indicative results demonstrating various aspects of the clinical adaptation and validation process are presented. Completion of these processes is expected to pave the way for the ultimate clinical translation of the systems.
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi